The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

This study is testing whether empagliflozin (a medication typically used for diabetes and heart disease) can protect the kidneys in patients who are hospitalized with heart failure and also developing acute kidney injury — a condition called cardiorenal syndrome type 1. **You may be eligible if...** - You are 18 or older - You are in the hospital primarily because of heart failure (new or worsening) - You are showing early signs of kidney stress or injury (diagnosed within 12 hours) **You may NOT be eligible if...** - You are in cardiogenic shock or have unstable blood pressure - You have had a recent heart attack - Your kidneys are severely damaged (very low kidney function) or you need dialysis - You have type 1 diabetes or a history of diabetic ketoacidosis - You have had a heart or kidney transplant - You have taken a similar medication (SGLT2 inhibitor) in the past 3 months - You are pregnant - You have a terminal illness with less than 1 month expected survival Talk to your doctor to see if this trial is right for you.